HEMAB THERAPEUTICS HOLDINGS INC (COAG)
NASDAQHealth CareBiotechnologySnapshot 2026-10-16
$30.07-7.53%
Close 2026-10-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-16
Research Workspace
Put COAG beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 48% in its worst 12-month stretch.
View RiskCOAG’s bet rests on HMB-003 advancing through clinical trials and the pipeline. The desk lacks enough revenue history to establish a growth trend. Q2 FY2026 reported GAAP earnings per share of negative 0.8. No latest earnings release is recorded. A Seeking Alpha analyst says the market reflects only one pipeline stage. That analyst’s view is opinion, not company guidance. COAG’s valuation bridge has no usable current or peer multiple. The desk says the price roughly matches forecast growth. A next-quarter miss probability of 46% makes trial progress a specific risk. The article cites clot risk, competition, and small clinical samples. Peer multiples imply a price about 39% above where it trades. This read is provisional.
Trailing returns as of 2026-10-16. COAG is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering COAG (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for COAG in the last 4 months.
Continue this research
Compare COAG with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| COAG Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-16. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put COAG next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Highlights multiple clinical catalysts supporting valuation.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-16. EPS is implied from price ÷ P/E. Not investment advice.
Current $30.07
The last 12 months of price, then the range of analyst 12-month targets from today’s $30.07.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Positive data on Sutacimig supports product potential.
Presentation of clinical data enhances product credibility.
Presentation of clinical data enhances product credibility.
Presentation of clinical data enhances product credibility.
Advancement in pipeline indicates strong product development.
Positive assessment of HMB-002 for a specific condition.
New clinical data supports product efficacy.
